Key Takeaways
- Researchers developed a low-cost, paper-based test for cardiac troponin I that delivers results in 15 minutes.
- The test costs $4, with an additional portable reader priced at $170, making it accessible for underserved populations.
- The new technology enhances diagnostic accuracy and has the potential to improve global health outcomes related to heart disease.
Revolutionary Cardiac Testing Technology
In the critical moments following a heart attack, timely detection and diagnosis are crucial to survival. Traditional methods often rely on expensive laboratory equipment and require immediate access to advanced medical facilities. However, advancements from researchers at the U.S. National Science Foundation’s Precise Advanced Technologies and Health Systems for Underserved Populations (NSF PATHS-UP) Engineering Research Center present a transformative solution.
The team has developed a novel, paper-based test that measures cardiac troponin I (cTnI), a key biomarker indicative of a heart attack, providing results in as little as 15 minutes. This innovative approach not only reduces costs linked to testing but also enhances accessibility, particularly for populations lacking access to medical care.
Aydogan Ozcan, Volgenau Chair for Engineering Innovation at UCLA and part of the NSF PATHS-UP executive committee, highlighted the significance of this development. He stated, “We are excited to introduce this low-cost, portable solution that bridges the gap between central laboratory diagnostics and point-of-care testing.” This paper-based platform harnesses deep learning technology to deliver an efficient alternative to conventional, bulky medical instruments prevalent in hospitals.
According to research published in ACS Nano, the deep learning-enhanced paper test employs a vertical flow assay that boasts high sensitivity for detecting cTnI. Each test is estimated to cost only $4, while the accompanying portable reader, designed with a Raspberry Pi and readily available components, is priced at approximately $170. The researchers foresee these cutting-edge diagnostic tools transitioning into commercial use through licensing arrangements or spin-off companies.
Experimental comparisons with existing point-of-care devices reveal that the new tests not only satisfy clinical testing requirements but outperform them in terms of sensitivity. Enhancing access to diagnostic testing holds the potential to significantly improve health outcomes globally, particularly by mitigating the high cardiovascular disease mortality rate, which claims around 19 million lives annually. The availability of rapid and sensitive tests is especially crucial for underserved populations, where immediate access to medical facilities is often limited.
“The PATHS-UP researchers have achieved a highly effective solution by leveraging a paper-based platform to minimize costs while incorporating machine learning for enhanced diagnostic accuracy,” commented Lan Wang, program director for the NSF Division of Engineering Education and Centers. This initiative not only makes advanced health technology more affordable but also contributes to workforce development by training a diverse range of scientists and engineers. These efforts are aimed at creating enabling technologies that address health disparities in communities with limited access to medical care.
Through these advancements, the potential for improved health outcomes in vulnerable populations is promising, potentially leading to a future where timely diagnosis and intervention significantly reduce the risks and impacts of cardiovascular diseases.
The content above is a summary. For more details, see the source article.